Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety
Diabetes/Metabolism Research and Reviews · 2025-09 · 41 (6)
DOI: 10.1002/dmrr.70075 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 06.08.2025. Verfasst von Yonglu Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Mineralocorticoid Receptor Antagonists, Naphthyridines, Diabetic Nephropathies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 104 Literaturangaben. Gefördert von: Taishan Young Scholar Program of Shandong Province, Shandong Higher Education Young Science and Technology Support Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a major global health issue that significantly impacts patients' quality of life and places a substantial burden on healthcare systems. Overactivation of the mineralocorticoid receptor (MR) plays a crucial role in kidney damage by promoting inflammation, fibrosis, and functional deterioration. Finerenone, a third‐generation highly selective non‐steroidal MR antagonist (MRA), has emerged as a promising therapeutic option for CKD. In this review, we discuss the mechanisms through which MR overactivation contributes to renal damage, the structural and pharmacokinetic characteristics of finerenone, and compare it with first‐ and second‐generation MRAs. We also focus on the safety and efficacy of finerenone in clinical applications for CKD. Notably, finerenone demonstrated a reduction in the risk of hyperkalemia during treatment, with its high selectivity minimising treatment‐related hormonal imbalances, offering a novel perspective. Furthermore, we explore the promising future of finerenone in both diabetic kidney disease (DKD) and non‐diabetic CKD, presenting updates from recent clinical trials and new insights into its potential role in these populations. In clinical practice, combining finerenone with sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors and renin‐angiotensin system (RAS) inhibitors has demonstrated strong cardiorenal protective effects. However, further clinical evidence is needed regarding direct combinations of finerenone with RAS inhibitors. Future studies on their synergistic effects may provide valuable insights. Ultimately, we hope this review offers new perspectives on finerenone's clinical applications and its future therapeutic prospects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China.
ORCID-Profile: Yangang Wang, Bingzi Dong
Förderung
- Taishan Young Scholar Program of Shandong Province
- Shandong Higher Education Young Science and Technology Support Program
- National Natural Science Foundation of China
Zitieren
APA
Hu, Y., Li, C., Li, S., Xu, L., Wang, Y., & Dong, B. (2025). Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety. Diabetes/Metabolism Research and Reviews, 41(6). https://doi.org/10.1002/dmrr.70075
Vancouver
Hu Y, Li C, Li S, Xu L, Wang Y, Dong B. Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety. Diabetes/Metabolism Research and Reviews. 2025;41(6). doi:10.1002/dmrr.70075
BibTeX
@article{Hu2025,
author = {Hu, Yonglu and Li, Chengqian and Li, Shufa and Xu, Lili and Wang, Yangang and Dong, Bingzi},
title = {Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2025},
volume = {41},
number = {6},
doi = {10.1002/dmrr.70075}
}
EUVIMED